Table 1. Overall survival (OS) of advanced or metastatic NSCLC patients following treatment with TKIs (phase IIB/III trials).

Drug	Study design	ΔOS (months)	Reference
Nintedanib	Docetaxel vs. docetaxel plus nintedanib (N=1,314; LUME-Lung 1)*	2.3 (HR =0.83)	Reck et al. (12)
Gefitinib	Platinium-based doublet chemotherapy, followed by either placebo or gefitinib (N=296; INFORM)	15.9 (HR =0.39)	Zhang et al. (13)
Afatinib	Cisplatin plus pemetrexate vs. cisplatin, pemetrexate plus afatinib (N=345; LUX-Lung 3)**	12.2 (HR =0.54)	Yang et al. (8)
Afatinib	Cisplatin plus gemcitabine vs. cisplatin, gemcitabine plus afatinib (N=364; LUX-Lung 6)**	13.0 (HR =0.64)	Yang et al. (8)
Afatinib	Afatinib vs. erlotinib (N=795; LUX-Lung 8)***	1.1 (HR =0.81)	Soria et al. (14)
Afatinib	Afatinib vs. gefitinib (N=319; LUX-Lung 7)****	Alive at 24 months: 18% vs. 8% (P=0.018)	Park et al. (9)
Dacomitinib	Dacomitinib vs. gefitinib (N=440; ARCHER1050)	Awaited Q1/2017	www.clinicaltrials.gov (10)

*, adenocarcinoma only; **, meta-analysis for del19 patients; ***, squamous histology only; ****, OS data not yet mature.